[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": [
            "ImmTAC",
            "Immunotherapy",
            "Bispecific T cell receptor fusion protein",
            "Immune mobilizing monoclonal T cell receptor against cancer",
            "Checkpoint inhibitor",
            "PD1 / PD-1",
            "PD-L1 / PDL1",
            "Melanoma",
            "Lung Cancer",
            "Ovarian Cancer",
            "Endometrial Cancer",
            "Triple Negative Breast Cancer",
            "NSCLC"
        ],
        "dcp_id": null,
        "interventional_model": "SEQUENTIAL_ASSIGNMENT",
        "lead_org": "Immunocore Ltd",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "ECOG PS 0 or 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "HLA-A*02:01 positive"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "PRAME positive tumor"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Relapsed from, refractory to, or intolerant of standard therapy"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "If applicable, must agree to use highly effective contraception"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 6,
                    "description": "Symptomatic or untreated central nervous system metastasis"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 7,
                    "description": "Recent bowel obstruction"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 8,
                    "description": "Ascites requiring recurrent paracentesis"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 9,
                    "description": "Significant immune-mediated adverse event with prior immunotherapy (patients in checkpoint inhibitor combination treatment)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 10,
                    "description": "Inadequate washout from prior anticancer therapy"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 11,
                    "description": "Significant ongoing toxicity from prior anticancer treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 12,
                    "description": "Out-of-range laboratory values"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 13,
                    "description": "Clinically significant lung, heart, or autoimmune disease"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 14,
                    "description": "Ongoing requirement for immunosuppressive treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 15,
                    "description": "Prior solid organ or bone marrow transplant"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "Known history of human immunodeficiency virus (HIV)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "Significant secondary malignancy"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Hypersensitivity to study drug or excipients"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study intervention"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 21,
                    "description": "Pregnant or lactating"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "Any other contraindication for applicable combination partner based on local prescribing information"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "The IMC-F106C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable\r\n      tumors which include select Advanced Solid Tumors and will be conducted in two phases.\r\n\r\n        1. Phase 1: To identify the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 dose\r\n           (RP2D) of IMC-F106C as a single agent and administered in combination with a checkpoint\r\n           Inhibitor, chemotherapy, or another ImmTAC molecule.\r\n\r\n        2. Phase 2: To assess the efficacy of IMC-F106C as a single agent in selected advanced\r\n           solid tumors.",
        "official_title": "Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers",
        "_phase_sort_order": 3,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "approximately 3 weeks",
                "name": "Changes in lymphocyte counts over time",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "approximately 3 weeks",
                "name": "Changes in serum cytokines over time",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "from first dose to approximately 2 years",
                "name": "Duration of response (DOR)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "approximately 2 years",
                "name": "Incidence of anti-IMC-F106C antibody formation",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "from first dose to approximately 2 years",
                "name": "Overall survival",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "approximately 3 weeks (IMC-F106C AUC will be assessed for ~3 weeks)",
                "name": "Pharmacokinetics Area under the plasma concentration-time curve (AUC)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "approximately 3 weeks (IMC-F106C t1/2 will be assessed for ~ 3 weeks)",
                "name": "Pharmacokinetics The elimination half-life (t1/2)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "approximately 3 weeks (IMC-F106C Cmax will be assessed for ~3 weeks)",
                "name": "Pharmacokinetics The maximum observed plasma drug concentration (Cmax)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "approximately 3 weeks (IMC-F106C Tmax will be assessed for ~3 weeks)",
                "name": "Pharmacokinetics The time to reach maximum plasma concentration (Tmax)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "from first dose to 30 days after the last dose",
                "name": "Phase 1: changes in electrocardiogram parameters",
                "description": "QTcF interval absolute values and changes from baseline will be summarized",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "from first dose to 30 days after the last dose",
                "name": "Phase 1: changes in laboratory parameters",
                "description": "Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) laboratory abnormalities",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "from first dose to 30 days after the last dose",
                "name": "Phase 1: changes in vital signs",
                "description": "Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) vital sign abnormalities",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "from first dose through last dose (anticipated for up to 12 months)",
                "name": "Phase 1: dose interruptions, reductions, and discontinuations",
                "description": "Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to adverse event Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to treatment-related adverse event",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "from first dose to 30 days after the last dose",
                "name": "Phase 1: incidence and severity of adverse events (AE) and serious adverse events (SAE)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "From first dose to DLT period (28 days)",
                "name": "Phase 1: Incidence of Dose-limiting toxicity (DLT)s",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "from first dose to approximately 2 years",
                "name": "Phase 2: Best overall response (BOR)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "from first dose to approximately 2 years",
                "name": "Phase I: Best Overall Response (BOR)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "from first dose to approximately 2 years",
                "name": "Progression-free survival (PFS)",
                "description": null,
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I_II",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 4,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT04262466",
        "biomarkers": [
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "HLA-A*02 Positive",
                    "HLA-A*02 Positive Cells Present",
                    "HLA-A*2 Positive",
                    "HLA-A02 Allele Positive",
                    "HLA-A02 Positive",
                    "HLA-A2 Positive"
                ],
                "nci_thesaurus_concept_id": "C69408",
                "name": "HLA-A2 Positive Cells Present",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C28585",
                    "C16612",
                    "C36292",
                    "C25790",
                    "C16812",
                    "C16617",
                    "C77140",
                    "C3367",
                    "C35682",
                    "C177692"
                ],
                "parents": [
                    "C177692",
                    "C28585"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Positive",
                    "positive test result"
                ],
                "nci_thesaurus_concept_id": "C35682",
                "name": "Positive Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C77140",
                    "C3367",
                    "C36292"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25790",
                "name": "Immunoprotein Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Genes"
                ],
                "nci_thesaurus_concept_id": "C16612",
                "name": "Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "PRAME",
                    "Preferentially Expressed Antigen in Melanoma Gene"
                ],
                "nci_thesaurus_concept_id": "C127928",
                "name": "PRAME Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "ancestors": [
                    "C54362",
                    "C16612"
                ],
                "parents": [
                    "C54362"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "CT130 Positive",
                    "Cancer/Testis Antigen 130 Positive",
                    "MAPE Positive",
                    "Melanoma Antigen Preferentially Expressed in Tumors Positive",
                    "OIP-4 Positive",
                    "OIP4 Positive",
                    "Opa-Interacting Protein 4 Positive",
                    "PRAME Expression Positive",
                    "Preferentially Expressed Antigen in Melanoma Positive"
                ],
                "nci_thesaurus_concept_id": "C133814",
                "name": "PRAME Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C16612",
                    "C36292",
                    "C77140",
                    "C54362",
                    "C3367",
                    "C35682",
                    "C127928",
                    "C177692"
                ],
                "parents": [
                    "C127928",
                    "C177692"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Observable Entity"
                ],
                "nci_thesaurus_concept_id": "C3367",
                "name": "Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "HLA-A*0201 Positive",
                    "HLA-A*02:01 Positive Cells Present"
                ],
                "nci_thesaurus_concept_id": "C69178",
                "name": "HLA-A*0201 Positive Cells Present",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C25790",
                    "C3367",
                    "C28585",
                    "C16812",
                    "C69408",
                    "C35682",
                    "C36292",
                    "C16617",
                    "C16612",
                    "C129450",
                    "C77140",
                    "C177692"
                ],
                "parents": [
                    "C129450",
                    "C28585",
                    "C69408"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "HLA-A",
                    "Major Histocompatibility Complex, Class I, A Gene"
                ],
                "nci_thesaurus_concept_id": "C28585",
                "name": "HLA-A Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "ancestors": [
                    "C16812",
                    "C16612",
                    "C25790",
                    "C16617"
                ],
                "parents": [
                    "C16617"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C54362",
                "name": "Transcription Regulation Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Diagnostic Test Result",
                    "Test Result"
                ],
                "nci_thesaurus_concept_id": "C77140",
                "name": "Clinical Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "ancestors": [
                    "C3367"
                ],
                "parents": [
                    "C3367"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "LAB_RESULT",
                    "Lab Findings",
                    "Lab Value",
                    "Laboratory Finding",
                    "Laboratory Report",
                    "Labs",
                    "Test Result",
                    "test_result"
                ],
                "nci_thesaurus_concept_id": "C36292",
                "name": "Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "HLA-A*0201 Positive"
                ],
                "nci_thesaurus_concept_id": "C129450",
                "name": "HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C25790",
                    "C3367",
                    "C28585",
                    "C16812",
                    "C16617",
                    "C35682",
                    "C36292",
                    "C16612",
                    "C77140",
                    "C177692"
                ],
                "parents": [
                    "C177692",
                    "C28585"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Expressed",
                    "Expression Detected"
                ],
                "nci_thesaurus_concept_id": "C177692",
                "name": "Expression Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C77140",
                    "C3367",
                    "C35682",
                    "C36292"
                ],
                "parents": [
                    "C35682"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Class I MHC",
                    "MHC Class I"
                ],
                "nci_thesaurus_concept_id": "C16617",
                "name": "MHC Class I Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16812",
                    "C16612",
                    "C25790"
                ],
                "parents": [
                    "C16812"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "HLA Complex Gene"
                ],
                "nci_thesaurus_concept_id": "C16812",
                "name": "Major Histocompatibility Complex Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612",
                    "C25790"
                ],
                "parents": [
                    "C25790"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            }
        ],
        "classification_code": null,
        "current_trial_status_date": "2020-02-25",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrent Solid Tumor",
                    "Relapsed Malignant Solid Neoplasm",
                    "Recurrent Malignant Solid Neoplasm",
                    "Relapsed Solid Neoplasm",
                    "Relapsed Solid Tumor",
                    "Recurrent Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127153",
                "name": "Recurrent Malignant Solid Tumor",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C132146",
                    "C4813"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Solid Tumor",
                    "Advanced Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9270",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133737",
                "name": "Refractory Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C132146",
                    "C120186"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Malignant Solid Neoplasm",
                    "Metastatic Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Neoplasm",
                    "Solid Tumour",
                    "Solid tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Neoplasm Recurrence",
                    "Recurrence",
                    "Recurrent Tumor",
                    "Recurrent"
                ],
                "nci_thesaurus_concept_id": "C4798",
                "name": "Recurrent Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrence",
                    "Recurrent Cancer",
                    "Recurrent Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C4813",
                "name": "Recurrent Malignant Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4798",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Cancer",
                    "resistant cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "IMC-F106C-101",
        "active_sites_count": 8,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1512",
                        "name": "Immunoconjugate",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C16203",
                        "name": "Clinical or Research Activity",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C43431"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C128057",
                        "name": "Anti-PD-L1 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C191689",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-PD-1 Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C128037",
                        "name": "Anti-PD1 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C124946",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C143250",
                        "name": "Immune Checkpoint Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C141144"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "PD-L1-targeting Agent",
                            "CD274-targeting Agent",
                            "Anti-PD-L1 Agent",
                            "Anti-CD274 Agent"
                        ],
                        "nci_thesaurus_concept_id": "C191689",
                        "name": "PD-L1 Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C156893"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Programmed Cell Death Protein 1 Inhibitor",
                            "Anti-PD-1 Agent",
                            "PD-1-targeting Agent",
                            "PD-1 Inhibitor",
                            "Protein PD-1 Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C124946",
                        "name": "PD1 Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C163758",
                            "C143250"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Intervention Strategies",
                            "Procedure",
                            "Intervention"
                        ],
                        "nci_thesaurus_concept_id": "C25218",
                        "name": "Intervention or Procedure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C16203"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Substance",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals",
                            "Drug",
                            "Pharmacologic Agent",
                            "Pharmacological Substance",
                            "Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Tecentriq"
                        ],
                        "nci_thesaurus_concept_id": "C106250",
                        "name": "Atezolizumab",
                        "description": "A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1) with potential immunomodulating and antineoplastic activities. Anti-PD-L1 monoclonal antibody MPDL3280A binds to PD-L1, blocking its binding to and activation of its receptor, PD-1 (programmed death 1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1. PD-L1 is overexpressed on many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)",
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C128057"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C141144",
                        "name": "Immune Checkpoint Modulator",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Therapeutic Interventions",
                            "Therapy",
                            "Therapeutic Technique",
                            "Therapeutic Method"
                        ],
                        "nci_thesaurus_concept_id": "C49236",
                        "name": "Therapeutic Procedure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Monoclonal Antibodies",
                            "Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C20401",
                        "name": "Monoclonal Antibody Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immune Mediators",
                            "Immune Modulators",
                            "Immunopotentiators",
                            "Immunomodulatory Agent",
                            "Immunotherapy Agent",
                            "Immunotherapeutic Agent",
                            "Immune Regulators",
                            "BRM",
                            "Biomodulators",
                            "Immunomodulators",
                            "Immunomodulating Agent",
                            "Biological Response Modifier"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Molecularly Targeted Therapy Agent",
                            "Anti-tumor Targeted Therapy Agent",
                            "Targeted Agent",
                            "Targeted Therapeutic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C163758",
                        "name": "Targeted Therapy Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Kimmtrak"
                        ],
                        "nci_thesaurus_concept_id": "C94208",
                        "name": "Tebentafusp",
                        "description": "A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of IMCgp100 into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C1512"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Keytruda"
                        ],
                        "nci_thesaurus_concept_id": "C106432",
                        "name": "Pembrolizumab",
                        "description": "A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C128037"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C43431",
                        "name": "Activity",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastics",
                            "Anti-Cancer Agents",
                            "Antineoplastic Drugs",
                            "Antiproliferative Agents",
                            "Tumor-Specific Treatment Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Tumor Agents",
                            "Antiproliferative Drugs",
                            "Cancer Drug",
                            "Anti-Tumor Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "PD-1 Ligands Inhibitor",
                            "PD-1 Ligand-targeting Agent"
                        ],
                        "nci_thesaurus_concept_id": "C156893",
                        "name": "PD-1 Ligand Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C143250",
                            "C163758"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C170976",
                        "name": "Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C15632",
                        "name": "Chemotherapy",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C49236"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biopharmaceuticals",
                            "Immunologic, Immunochemical",
                            "Immunologics",
                            "Biological Products",
                            "Biologicals",
                            "Biologics"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1",
                "description": "Dose Escalation",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "IMC-F106C and another ImmTAC - Arm D - Phase 1",
                "description": "Dose Escalation",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "IMC-F106C and chemotherapy - Arm C - Phase 1",
                "description": "Dose Escalation",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "IMC-F106C - Arm A - Phase 1 and Phase 2",
                "description": "Phase 1 dose escalation and Phase 2 monotherapy dose expansion",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2020-02152",
        "why_study_stopped": null,
        "brief_summary": "IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC \u00ae)\r\n      designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This\r\n      is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult\r\n      patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME",
        "brief_title": "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors",
        "status_history": [
            {
                "status_date": "2020-02-25T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 170,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2020-02-25",
        "record_verification_date": "2023-03-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": null,
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2026-02-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]